SLC5A2 and diabetes mellitus: In patients with DM, 50.0% were on the prescription of metformin, 6.0% were on a glucagon-like peptide-1 (GLP-1) receptor agonist, 52.4% were on a sodium‒glucose cotransporter 2 (SGLT2) inhibitor, and 22.6% were on a dipeptidyl peptidase-4 (DPP-4) inhibitor.